Change search
ReferencesLink to record
Permanent link

Direct link
Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register
Show others and affiliations
2013 (English)In: BMJ Open, ISSN 2044-6055, Vol. 3, no 4, e002688- p.Article in journal (Refereed) Published
Abstract [en]

Objectives To investigate the benefits and risks associated with aspirin treatment in patients with type 2 diabetes and no previous cardiovascular disease (CVD) in clinical practice. Design Population-based cohort study between 2005 and 2009, mean follow-up 3.9years. Setting Hospital outpatient clinics and primary care in Sweden. Participants Men and women with type 2 diabetes, free from CVD, including atrial fibrillation and congestive heart failure, at baseline, registered in the Swedish National Diabetes Register, with continuous low-dose aspirin treatment (n=4608) or no aspirin treatment (n=14038). Main outcome measures Risks of CVD, coronary heart disease (CHD), stroke, mortality and bleedings, associated with aspirin compared with no aspirin, were analysed in all patients and in subgroups by gender and estimated cardiovascular risk. Propensity scores were used to adjust for several baseline risk factors and characteristics at Cox regression, and the effect of unknown covariates was evaluated in a sensitivity analysis. Results There was no association between aspirin use and beneficial effects on risks of CVD or death. Rather, there was an increased risk of non-fatal/fatal CHD associated with aspirin; HR 1.19 (95% CI 1.01 to 1.41), p=0.04. The increased risk of cardiovascular outcomes associated with aspirin was seen when analysing women separately; HR 1.41 (95% CI 1.07 to 1.87), p=0.02, and HR 1.28 (95% CI 1.01 to 1.61), p=0.04, for CHD and CVD, respectively, but not for men separately. There was a trend towards increased risk of a composite of bleedings associated with aspirin, n=157; HR 1.41 (95% CI 0.99 to 1.99). Conclusions The results support the trend towards more restrictive use of aspirin in patients with type 2 diabetes and no previous CVD. More research is needed to explore the differences in aspirin's effects in women and men.

Place, publisher, year, edition, pages
BMJ Publishing Group , 2013. Vol. 3, no 4, e002688- p.
Keyword [en]
Diabetes & Endocrinology, Epidemiology
National Category
Public Health, Global Health, Social Medicine and Epidemiology Endocrinology and Diabetes
URN: urn:nbn:se:umu:diva-86087DOI: 10.1136/bmjopen-2013-002688ISI: 000329809200005OAI: diva2:696967
Available from: 2014-02-17 Created: 2014-02-17 Last updated: 2014-02-17Bibliographically approved

Open Access in DiVA

fulltext(415 kB)399 downloads
File information
File name FULLTEXT01.pdfFile size 415 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Fhärm, EvaRolandsson, Olov
By organisation
Family Medicine
In the same journal
BMJ Open
Public Health, Global Health, Social Medicine and EpidemiologyEndocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar
Total: 399 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 69 hits
ReferencesLink to record
Permanent link

Direct link